Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection

References

• WHO [webpage on the Internet]WHO Fact Sheet on Hepatitis B2016 Available from: http://www.who.int/mediacentre/factsheets/fs204/en/Accessed March 14, 2017
   Google Scholar
• ShinJHKwonHJJangHRRisk factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agentsMedicine (Baltimore)2016951e240026735542
   PubMed Web of Science ®Google Scholar
• Rodríguez-NóvoaSGarcía-SamaniegoJPrietoMAltered underlying renal tubular function in patients with chronic hepatitis B receiving nucleos(t)ide analogs in a real-world setting: the MENTE studyJ Clin Gastroenterol201650977978927332746
   PubMed Web of Science ®Google Scholar
• PolSLamperticoPFirst-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practiceJ Viral Hepat201219637738622571899
   PubMed Web of Science ®Google Scholar
• WuXCaiSLiZPotential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysisVirol J2016136427062520
   PubMed Web of Science ®Google Scholar
• LamperticoPChanHLJanssenHLStrasserSISchindlerRBergTReview article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patientsAliment Pharmacol Ther2016441163427198929
   PubMed Web of Science ®Google Scholar
• ChanHLShaikhJGuptaSHamedKRenal function in nucleos(t) ide analog-treated patients with chronic hepatitis B: a systematic literature review and network meta-analysisAdv Ther201633586287527146675
   PubMed Web of Science ®Google Scholar
• ChackoECSurrunSKMubarack SaniTPPappachanJMChronic viral hepatitis and chronic kidney diseasePostgrad Med J201086101848649220709771
   PubMed Web of Science ®Google Scholar
• BhimmaRCoovadiaHMHepatitis B virus-associated nephropathyAm J Nephrol200424219821114988643
   PubMed Web of Science ®Google Scholar
• YiZJieYWNanZThe efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: a systematic review and meta-analysisAnn Hepatol201110216517321502678
   PubMed Web of Science ®Google Scholar
• FabriziFDixitVMartinPMeta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritisAliment Pharmacol Ther200624578178816918881
   PubMed Web of Science ®Google Scholar
• LaiKNLiPKLuiSFMembranous nephropathy related to hepatitis B virus in adultsN Engl J Med199132421145714632023605
   PubMed Web of Science ®Google Scholar
• AppelGViral infections and the kidney: HIV, hepatitis B, and hepatitis CCleve Clin J Med200774535336017506240
   PubMed Web of Science ®Google Scholar
• FontanaRJSide effects of long-term oral antiviral therapy for hepatitis BHepatology2009495 supplS185S19519399802
   PubMed Web of Science ®Google Scholar
• Riveiro-BarcielaMTaberneroDCallejaJLEffectiveness and safety of entecavir or tenofovir in a Spanish cohort of chronic hepatitis B patients: validation of the page-G score to predict hepatocellular carcinomaDig Dis Sci201762378479328078526
   PubMed Web of Science ®Google Scholar
• KoksalARAlkimHBogaSValue of cystatin C-based e-GFR measurements to predict long-term tenofovir nephrotoxicity in patients with hepatitis BAm J Ther Epub2016104
   Google Scholar
• López CentenoBCollado BorrellRPérez EncinasMGutiérrez GarcíaMLSanmartin FenolleraPComparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis BFarm Hosp201640427928627571496
   PubMedGoogle Scholar
• ZoulimFBiałkowska-WarzechaJDiculescuMMEntecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failureHepatol Int201610577978827206517
   PubMed Web of Science ®Google Scholar
• SriprayoonTMahidolCUngtrakulTEfficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trialHepatol Res2017473E161E16827176630
   PubMed Web of Science ®Google Scholar
• TsaiMCChenCHTsengPLDoes nucleos(t)ide analogues treatment affect renal function in chronic hepatitis B patients who have already decreased eGFR? A longitudinal studyPLoS One2016113e014976126964034
   PubMed Web of Science ®Google Scholar
• ParkJYKimCWBaeSHEntecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective studyLiver Int20163681108111526781724
   PubMed Web of Science ®Google Scholar
• WangHMHungCHLeeCMThree-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patientsJ Gastroenterol Hepatol20163171307131426758501
   PubMed Web of Science ®Google Scholar
• TsaiMCChenCHTsengPLComparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experienceClin Microbiol Infect201622195.e1e7
   PubMed Web of Science ®Google Scholar
• KokluSGulsenMTTunaYDifferences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis BAliment Pharmacol Ther201541331031925982037
   PubMed Web of Science ®Google Scholar
• KimBGJungSWKimEHTenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavirJ Gastroenterol Hepatol201530101514152125973716
   PubMed Web of Science ®Google Scholar
• HaNBKuKHaNBChaungKTTrinhHNNguyenMHRenal function in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or entecavir monotherapy: a matched case-cohort studyJ Clin Gastroenterol2015491087387725856383
   PubMed Web of Science ®Google Scholar
• LimYSYooBCByunKSTenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trialGut20166561042105125800784
   PubMed Web of Science ®Google Scholar
• HungCHHuTHLuSNTenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbationAntimicrob Agents Chemother20155963168317325779569
   PubMed Web of Science ®Google Scholar
• LimYSByunKSYooBCTenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trialGut201665585286025596179
   PubMed Web of Science ®Google Scholar
• QiXWangJYMaoRCZhangJMImpact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in ChinaJ Viral Hepat20152214654
   PubMed Web of Science ®Google Scholar
• TienCXuJJChanLSLong-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handlingDig Dis Sci201560256657225239496
   PubMed Web of Science ®Google Scholar
• LokASTrinhHCarosiGEfficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis BGastroenterology2012143361962822643350
   PubMed Web of Science ®Google Scholar
• GishRGClarkMDKaneSDShawREMangahasMFBaqaiSSimilar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis BClin Gastroenterol Hepatol201210894194622507876
   PubMed Web of Science ®Google Scholar
• LiawYFSheenISLeeCMTenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver diseaseHepatology2011531627221254162
   PubMed Web of Science ®Google Scholar
• Fernandez-FernandezBMontoya-FerrerASanzABTenofovir nephrotoxicity: 2011 updateAIDS Res Treat2011201135490821716719
   PubMedGoogle Scholar
• NelsonMRKatlamaCMontanerJSThe safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsAIDS2007211273128117545703
   PubMed Web of Science ®Google Scholar
• Product Information: VIREAD(R) oral tablets, tenofovir disoproxil fumarate oral tabletsFoster City, CAGilead Sciences, Inc.2010
   Google Scholar
• Product Information: BARACLUDE(R) oral tablets, solution, entecavir oral tablets, solutionPrinceton, NJBristol-Myers Squibb Company2009
   Google Scholar
• RuanePJDeJesusEBergerDAntiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adultsJ Acquir Immune Defic Syndr201363444945523807155
   PubMed Web of Science ®Google Scholar
• SaxPEWohlDYinMTTenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trialsLancet201538599872606261525890673
   PubMed Web of Science ®Google Scholar
• ButiMGaneESetoWKTenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialLancet Gastroenterol Hepatol20161319620628404092
   PubMed Web of Science ®Google Scholar
• ChanHLFungSSetoWKTenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialLancet Gastroenterol Hepatol20161318519528404091
   PubMed Web of Science ®Google Scholar
• WHO [webpage on the Internet]WHO Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection2015 Available from: http://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/Accessed May 30, 2017
   Google Scholar